A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions [INTERVENTIONAL]

CONCLUSIONS:
Cangrelor seems to be as safe as glycoprotein IIb/IIIa inhibitors for managing refractory intracranial occlusion and leads to satisfactory brain reperfusion. Cangrelor is a promising agent in this setting, and additional studies are warranted to confirm our findings.

Source: American Journal of Neuroradiology - August 11, 2021 Category: Radiology Authors: Marnat, G., Delvoye, F., Finitsis, S., Lapergue, B., Gariel, F., Consoli, A., Desilles, J.- P., Mazighi, M., Dargazanli, C., Bourcier, R., Darcourt, J., Chalumeau, V., Elhorany, M., Clarencon, F., Richard, S., Gory, B., Sibon, I., on behalf of the ETIS In Tags: INTERVENTIONAL Source Type: research